Table 1 Proportion of arrhythmic risk factors in Fabry cohorts
From: Cardiac device implantation and device usage in Fabry and hypertrophic cardiomyopathy
Fabry disease | |||
|---|---|---|---|
Primary prevention N = 36 | Secondary prevention N = 14 | p value | |
Age (years) | 58 ± 12 | 57 ± 12 | 0.922 |
Male gender (n, %) | 8 (22) | 2 (7) | 0.704 |
MSSI > 20 (n, %) | 10 (28) | 2 (14) | 0.468 |
LVH (n, %) | 32 (89) | 12 (86) | 1.000 |
LGE > 3 segments (n, %) | 11 (41) | 3 (11) | 0.115 |
Elevated troponin (n, %) | 7 (19) | 4 (29) | 0.476 |
QRS duration > 120 ms (n, %) | 21 (58) | 7 (50) | 0.719 |